Company: GEHC
Filing Date: 2025-10-29
Form Type: 10-Q
Source: 0001932393-25-000053
Chunk: 107

Company: GE HealthCare Technologies Inc.
Filing Date: 2025-10-29
Form: 10-Q
Item: Item 8
Chunk 107
---
, decreasing 3% or $17 million due to a decrease in AVS and PCS revenues, partially offset by growth in PDx revenues; and

•Rest of World revenues were $879 million, growing 8% or $63 million due to growth in PDx revenues, inclusive of NMP revenues, and Imaging revenues.

For the nine months ended September 30, 2025

Total revenues were $14,927 million, growing 4% as reported and 3% organically*. Sales of products increased 3% or $301 million primarily driven by strong growth in PDx, AVS, and Imaging revenues. Sales of services increased 6% or $274 million primarily driven by growth in new and existing customer contractual agreements.

The segment revenues were as follows:

•Imaging segment revenues were $6,693 million, growing 4% or $231 million, with growth in the USCAN and EMEA regions, partially offset by continued pressure in the China market;

•AVS segment revenues were $3,829 million, growing 4% or $138 million with strength in the U.S. market, partially offset by continued pressure in the China market;

•PCS segment revenues were $2,262 million, decreasing 2% or $36 million, largely driven by a challenging year-over-year comparison in Life Support Solutions; and

•PDx segment revenues were $2,110 million, growing 13% or $248 million as reported, driven by the acquisition of NMP and an increase in Organic revenue*. Organic revenue* grew 7% driven by continued growth in volume and price.

The regional revenues were as follows:

•USCAN revenues were $6,934 million, growing 5% or $352 million with growth across AVS, Imaging, and PDx segment revenues, partially offset by a decline in PCS revenues;

•EMEA revenues were $3,802 million, growing 5% or $185 million with growth in Imaging, PDx, and AVS revenues, as well as favorable foreign currency impacts;

•China region revenues were $1,704 million, decreasing 2% or $41 million with declines in Imaging, AVS, and PCS revenues partially offset by growth in PDx revenues; and

•Rest of World revenues were $2,487 million, growing 3% or $79 million with growth in PDx revenues, inclusive of NMP revenues, partially offset by unfavorable foreign currency impacts.

____________________

*Non-GAAP Financial Measure

34